12:00 AM
 | 
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TCN-202: Phase I started

Theraclone began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate single and multiple doses of IV TCN-202...

Read the full 72 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >